Is Esperion Therapeutics Inc halal to invest in?

As of July 2026, Esperion Therapeutics Inc 0ET.SG is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Esperion Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Esperion Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Esperion Therapeutics Inc?

Muslim investors may consider investing in Esperion Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Esperion Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Esperion Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Esperion Therapeutics Inc updated?

The Shariah compliance status of Esperion Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Esperion Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Esperion Therapeutics Inc?

You can check the latest Shariah compliance status of Esperion Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Esperion Therapeutics Inc 0ET.SG

Last Updated: Jul 10, 12:00 AM·XSTU

0ET.SG Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Esperion Therapeutics Inc is classified as not halal.

NOT HALAL

Report Source: 2026 1st Quarter Report

Esperion Therapeutics Inc. Stock Analysis 0ET.SG

Germany Health Care Small Cap Report: Q1, 2026

Esperion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 294 full-time employees. The company went IPO on 2013-06-24. The company markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.

Key Statistics of Esperion Therapeutics Inc (0ET.SG)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€2.75€2.78

Today's Open

€2.77

Volume

3050.00

P/E Ratio (TTM)

Financial Metrics & Statements of Esperion Therapeutics Inc (0ET.SG)

Super Investors Invested in Esperion Therapeutics Inc (0ET.SG)

FAQ's for Esperion Therapeutics Inc (0ET.SG)

As of July 2026, Esperion Therapeutics Inc 0ET.SG is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Esperion Therapeutics Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in Esperion Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Esperion Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Esperion Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Esperion Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.